We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Fundamental aspects
-
1. Inflammation and tissue homeostasis
- Prof. Herman Waldmann
-
2. Introduction to the immune system
- Prof. Herman Waldmann
-
3. Hematopoiesis: the making of an immune system
- Prof. Paul J. Fairchild
-
4. Inflammation: purposes, mechanisms and development
- Prof. Pietro Ghezzi
-
5. Phagocytosis
- Dr. Eileen Uribe-Querol
-
6. Regulated cell death mechanisms and their crosstalk with the immune system 1
- Dr. Luis Alberto Baena-Lopez
-
7. Regulated cell death mechanisms and their crosstalk with the immune system 2
- Dr. Luis Alberto Baena-Lopez
- Innate immunity
-
11. Cells of the innate immune system
- Prof. Kevin Maloy
-
12. Microbial recognition and the immune response
- Dr. Dana Philpott
-
13. Toll-like receptor signalling during infection and inflammation
- Prof. Luke O'Neill
- Intercellular mediators
-
14. Chemokines
- Dr. James E. Pease
-
15. Cytokines
- Prof. Iain McInnes
-
16. IL-1 family cytokines as the canonical DAMPs of the immune system
- Prof. Seamus Martin
-
17. Glycoimmunology
- Prof. Paula Videira
- Adaptive immunity B cells
-
20. Antigen recognition in the immune system
- Prof. Herman Waldmann
-
21. B cell biology
- Prof. Richard Cornall
-
22. Antibody structure and function: antibody structure
- Dr. Mike Clark
-
23. Antibody structure and function: antibody function
- Dr. Mike Clark
-
24. Antibody genes and diversity
- Dr. Mike Clark
-
25. In vivo antibody discovery and hybridoma technology
- Prof. Dr. Katja Hanack
-
26. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
28. The immunobiology of Fc receptors
- Prof. Mark Cragg
-
29. Immunoreceptors
- Prof. Anton van der Merwe
-
30. Affinity, avidity and kinetics in immune recognition
- Prof. Anton van der Merwe
- Adaptive immunity T cells
-
31. The thymus and T cell development: a primer
- Prof. Georg Holländer
-
32. Lineage decisions in the thymus: T cell lineage commitment
- Prof. Bruno Silva-Santos
-
33. Lineage decisions in the thymus: αβ and γδ T cell lineages
- Prof. Bruno Silva-Santos
-
34. CD4 T cell subsets
- Dr. Brigitta Stockinger
-
35. Cytotoxic T lymphocytes
- Prof. Gillian Griffiths
-
36. Gamma delta T-cells
- Prof. Bruno Silva-Santos
-
37. Tfh and Tfr cells
- Prof. Luis Graca
-
38. Tissue resident memory T cells (TRM)
- Dr. Marc Veldhoen
-
39. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
- The importance of the MHC in immunity
-
40. The MHC and MHC molecules 1
- Prof. Jim Kaufman
-
41. The MHC and MHC molecules 2
- Prof. Jim Kaufman
-
42. Natural killer cells
- Dr. Philippa Kennedy
-
44. NK cells in viral immunity
- Prof. Lewis Lanier
- Lymphocyte activation
-
45. Signal transduction by leukocyte receptors
- Dr. Omer Dushek
-
46. Immunological memory 1
- Prof. David Gray
-
47. Immunological memory 2
- Prof. David Gray
-
48. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
- Major cellular partners in immunity
-
49. The mononuclear phagocyte system - tissue resident macrophages: distribution and functions
- Prof. Emeritus Siamon Gordon
-
50. The mononuclear phagocyte system: tissue resident macrophages - activation and regulation
- Prof. Emeritus Siamon Gordon
-
51. Dendritic cells: professional antigen presenting cells
- Prof. Paul J. Fairchild
-
52. Mucosal immunology
- Prof. Daniel Mucida
- Immunological tolerance and regulation
-
53. Self-tolerance
- Prof. Herman Waldmann
-
54. Tolerance and autoimmunity
- Prof. Emerita Anne Cooke
-
55. The balance between intestinal immune homeostasis and inflammation
- Prof. Dr. Janneke Samsom
- Translational immunology - immune deficiency
-
56. Primary immunodeficiency disorders
- Dr. Smita Y. Patel
-
57. Changes in innate and adaptive immunity during human ageing 1
- Dr. Roel De Maeyer
-
58. Changes in innate and adaptive immunity during human ageing 2
- Dr. Roel De Maeyer
-
59. The aging immune system
- Prof. Ana Caetano
- Translational immunology - protection against pathogenic microbes
-
60. Immune responses to viruses
- Prof. Paul Klenerman
-
61. HIV and the immune system
- Prof. Quentin Sattentau
-
62. COVID-19: the anti-viral immune response
- Prof. Danny Altmann
-
63. Bacterial immune evasion
- Prof. Christoph Tang
-
64. The immunology underlying tuberculosis
- Prof. Thomas R. Hawn
-
65. Innate immunity to fungi
- Prof. Gordon D. Brown
-
66. Parasite immunity: introduction and Plasmodium
- Dr. Catarina Gadelha
-
67. Parasite immunity: Leishmania and Schistosoma
- Dr. Catarina Gadelha
-
68. Vaccination
- Dr. Anita Milicic
-
69. The history of vaccines 1
- Prof. Emeritus Anthony R. Rees
-
70. The history of vaccines 2
- Prof. Emeritus Anthony R. Rees
-
71. The history of vaccines 3
- Prof. Emeritus Anthony R. Rees
-
72. The science of vaccine adjuvants
- Dr. Derek O'Hagan
- Translational immunology - hypersensitivity, autoimmune disease and their management
-
73. Hypersensitivity diseases: type 1 hypersensitivity
- Prof. Herman Waldmann
-
74. Innate lymphoid cells in allergy
- Prof. Emeritus Shigeo Koyasu
-
75. Hypersensitivity diseases: type II-IV hypersensitivity
- Prof. Sara Marshall
-
76. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
77. Interleukin-17: from clone to clinic
- Prof. Leonie Taams
-
78. Autoimmunity and type 1 diabetes
- Prof. Emerita Anne Cooke
-
79. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
80. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
81. Monoclonal antibodies in haemato-oncology
- Prof. Mark Cragg
-
82. Therapeutic antibodies
- Dr. Geoffrey Hale
-
83. Neuroimmunometabolism
- Prof. Ana Domingos
-
84. The immunology of multiple sclerosis
- Dr. Joanne Jones
-
85. Understanding myasthenia gravis and advances in its management
- Prof. Henry J. Kaminski
-
86. The immunology underlying rheumatic diseases
- Dr. Hussein Al-Mossawi
-
88. Complement and lupus
- Prof. Marina Botto
-
89. Immune mechanisms in liver diseases
- Prof. Paul Klenerman
- Translational immunology - transplantation immunology
-
90. Principles of transplantation: overview of the immune response
- Prof. Emerita Kathryn Wood
-
91. Factors influencing outcomes in clinical transplantation 1
- Prof. Emerita Kathryn Wood
-
92. Factors influencing outcomes in clinical transplantation 2
- Prof. Emerita Kathryn Wood
- Translational immunology - cancer immunology
-
93. Cancer immunology
- Prof. Tim Elliott
-
94. Cancer immunotherapy
- Prof. Tim Elliott
-
95. Myeloid-derived suppressor cells in cancer
- Prof. Dmitry Gabrilovich
-
96. IL-2 in the immunotherapy of autoimmunity and cancer
- Prof. Thomas Malek
-
97. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
Printable Handouts
Navigable Slide Index
- Introduction
- Opportunities for immunotherapy
- Cancer immunity cycle
- Many points for therapeutic intervention
- Four dominant approaches to immunotherapy
- Cytotoxic antibodies
- Antibiotic-drug conjugates in trials
- Currently approved mAb for cancer
- Cytotoxic antibodies: mechanisms of action
- Cytotoxic antibodies: Rituximab (a-CD20)
- Passive CTL immunotherapy
- CAR T cells: engineered targeting
- CAR T cells: Kymirah (a-CD19)
- Checkpoint blockade: anti-CTLA4
- Checkpoint blockade: Ipilimumab (a-CTLA-4)
- Checkpoint blockade: anti-PD1 and anti-PDL1
- Nivolumab (a-PD1) and Durvalumab (a-PDL1)
- Not all patients respond to treatment
- Vaccination
- Vaccination: therapeutic vaccines
- Cell based vaccine (DC)
- Therapeutic cancer vaccine: Sipuleucel-T
- Tumour specific neoantigens (1)
- Tumour specific neoantigens (2)
- Current immunotherapy development landscape
- Common toxicities
- Prospects for immunotherapy
- Thank you
Topics Covered
- Opportunities for immunotherapy
- Cytotoxic antibodies
- Monoclonal antibodies
- CAR T cells: engineered targeting
- Checkpoint blockade treatment
- Therapeutic vaccines
- Tumour specific neoantigens
- Current immunotherapy development landscape
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Elliott, T. (2021, September 30). Cancer immunotherapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 23, 2024, from https://hstalks.com/bs/4562/.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Tim Elliott has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Cancer
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Tim Elliott.
I'm the Kidani Professor of Immuno-oncology.
I work at the University of Oxford in the UK.
In this lecture, I'm going to give a brief introduction
to the basic principles of cancer immunotherapy.
I recommend you listen to an accompanying lecture in the same series here
on cancer immunology and this would serve as
a good primer to the lecture you're about to see now.
0:25
This cartoon describes in very basic terms,
the relationship between our immune system and a growing tumor.
We know that it's possible to prime T-cells to tumor antigens.
Those T-cells, when they become activated,
can home into the site of tumor development in a tissue where they
join other tissue-resident lymphocytes and together, these can kill tumor cells.
And that this process of tumor ablation can balance any cell division that's
occurring in tumor cells and a period of so-called tumor equilibrium can ensue.
We also know, however,
that tumors can escape this immune attack either by
inducing functional exhaustion in T-cells or by inducing
any immunosuppressive tumor microenvironment by attracting suppressive cells to
the microenvironment or by
reprogramming tissue-resident cells to become immunosuppressive.
Well, the tumors can simply lose the ability to
present and process antigens to those T-cell.
They escape simply because they become invisible and this then leads
to a period of tumor progression which is clinically potentially lethal.
Now, each one of these stages is a potential target for immunotherapy.
I'll go through these in turn throughout my lecture.